Skip to main content

Advertisement

Table 1 Mean VA at baseline, 3 and 12 months following ranibizumab in CRVO patients categorised by pre-treatment clinical features

From: Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab

Pre-treatment clinical features Mean VA ± SD (ETDRS letters)
  N (%) Pre-Treatment 3 Months 12 Months
Base line VA (ETDRS letters) > 59 14 (27%) 64.6 ± 6.0 64.1 ± 18.5 54.8 ± 26.3
40–59 23 (44%) 49.8 ± 5.3 57.4 ± 17.0 45.2 ± 30.5
20–39 6 (12%) 32.8 ± 6.6 36.3 ± 20.4 30.8 ± 18.5
0–19 9 (17%) 0.6 ± 1.7 28.0 ± 31.4 21.2 ± 31.6
Age (years) ≥75 26 (50%) 40.3 ± 24.3 40.0 ± 24.5 24.7 ± 27.8
< 75 26 (50%) 46.3 ± 20.5 63.3 ± 18.1 59.3 ± 21.8
CWS Yes 26 (58%) 38.0 ± 25.5 40.8 ± 26.1 31.3 ± 30.4
No 19 (42%) 48.2 ± 20.2 61.5 ± 17.1 49.6 ± 24.9
Haemorrhages Multiple Deep Dark 29 (58%) 37.9 ± 25.7 45.8 ± 26.6 36.8 ± 30.7
Few Scattered 19 (38%) 47.6 ± 19.4 53.0 ± 21.0 42.8 ± 28.1
None 2 (4%) 60.0 ± 21.2 72.5 ± 17.7 27.5 ± 38.9
Foveal Detachment Yes 28 (62%) 46.0 ± 22.9 48.4 ± 24.9 40.6 ± 28.5
No 17 (38%) 38.2 ± 22.8 53.8 ± 21.7 37.4 ± 30.3
  1. VA Visual acuity, SD Standard deviation, ETDRS Early Treatment Diabetic Retinopathy Study, N number of eyes, CWS cotton wool spots